2-(Arylmethyl)-3-substituted quinuclidines as selective α7 nicotinic receptor ligands

[1]  R. Jules,et al.  Quinuclidine chemistry. 2. Synthesis and antiinflammatory properties of 2-substituted benzhydryl-3-quinuclidinols. , 1974, Journal of medicinal chemistry.

[2]  J. Campbell,et al.  Quinuclidine chemistry. I. Configuration and chemistry of 2-substituted benzylidene-3-quinuclidinones , 1974 .

[3]  Quinuclidine chemistry. 4. Diuretic properties of cis-3-amino-2-benzhydrylquinuclidine. , 1975 .

[4]  [3-Aminoquinuclidine carbamates, ureas, thio-ureas derivatives with potential parasiticidal activity (author's transl)]. , 1980, Annales pharmaceutiques francaises.

[5]  M. Langlois,et al.  Derivatives of quinuclidine as 5-HT3 receptor antagonists: influence of an additional carbonyl group on the recognition of chirality by the receptor. , 1993 .

[6]  R. Nannicini,et al.  Synthesis of a benzo[b]-1,5-naphthyridine derivative as a potential constrained NK1 receptor antagonist , 1994 .

[7]  D. Macintyre,et al.  Identification of a series of 3-(benzyloxy)-1-azabicyclo[2.2.2]octane human NK1 antagonists. , 1995, Journal of medicinal chemistry.

[8]  M. Bencherif,et al.  RJR-2403: a nicotinic agonist with CNS selectivity I. In vitro characterization. , 1996, The Journal of pharmacology and experimental therapeutics.

[9]  R. Papke,et al.  The correction of alpha7 nicotinic acetylcholine receptor concentration-response relationships in Xenopus oocytes , 1998, Neuroscience Letters.

[10]  M. Takeuchi,et al.  Selective muscarinic antagonists. II. Synthesis and antimuscarinic properties of biphenylylcarbamate derivatives. , 1998, Chemical & pharmaceutical bulletin.

[11]  J. Daly,et al.  6beta-Acetoxynortropane: a potent muscarinic agonist with apparent selectivity toward M2-receptors. , 1998, Journal of medicinal chemistry.

[12]  B. Potter,et al.  Characterisation of the binding of [3H]methyllycaconitine: a new radioligand for labelling α7-type neuronal nicotinic acetylcholine receptors , 1999, Neuropharmacology.

[13]  J. Schmitt,et al.  Chapter 5. Targeting nicotinic acetylcholine receptors: Advances in molecular design and therapies , 2000 .

[14]  M. Bencherif,et al.  TC-2559: a novel orally active ligand selective at neuronal acetylcholine receptors. , 2000, European journal of pharmacology.

[15]  J. Macor,et al.  (-)-Spiro[1-azabicyclo[2.2.2]octane-3,5'-oxazolidin-2'-one], a conformationally restricted analogue of acetylcholine, is a highly selective full agonist at the alpha 7 nicotinic acetylcholine receptor. , 2000, Journal of medicinal chemistry.

[16]  R. Papke,et al.  The Activation and Inhibition of Human Nicotinic Acetylcholine Receptor by RJR‐2403 Indicate a Selectivity for the α4β2 Receptor Subtype , 2000 .

[17]  J. Schmitt,et al.  Exploring the nature of molecular recognition in nicotinic acetylcholine receptors. , 2000, Current medicinal chemistry.

[18]  J. Schmitt,et al.  Targeting neuronal nicotinic receptors: a path to new therapies. , 2002, Current drug targets. CNS and neurological disorders.

[19]  R. Schreiber,et al.  AR-R 17779 improves social recognition in rats by activation of nicotinic α7 receptors , 2004, Psychopharmacology.

[20]  M. Dart,et al.  Design of ligands for the nicotinic acetylcholine receptors: the quest for selectivity. , 2004, Current topics in medicinal chemistry.

[21]  G. Dunbar,et al.  TC-1734: an orally active neuronal nicotinic acetylcholine receptor modulator with antidepressant, neuroprotective and long-lasting cognitive effects. , 2006, CNS drug reviews.

[22]  A. Gelain,et al.  Neuronal nicotinic acetylcholine receptor agonists , 2004 .

[23]  R. Papke,et al.  The Neuroprotective Effect of 2-(3-Pyridyl)-1-azabicyclo[3.2.2]nonane (TC-1698), a Novel α7 Ligand, Is Prevented through Angiotensin II Activation of a Tyrosine Phosphatase , 2004, Journal of Pharmacology and Experimental Therapeutics.